As per Future Market Insights' latest industry analysis, the U.S. animal model market was valued at over US$ 921.9 Mn in 2021 and is anticipated to exhibit a CAGR of close to 4.1% over the forecast period (2022-2032).

Animal models are predominantly used to gather information regarding the disease and its prevention, diagnosis, and treatment. They are being used to resolve a wide range of scientific concerns, ranging from basic science to the discovery and evaluation of new vaccines and therapies. Animals are used because of the similarities in biology across most mammals.

Get Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-14527

Personalized medicine is also known as precision medicine which utilizes data about a specific patient or an individual's genes to plan treatment for a disease. Animal models can play important role in the development of new approaches for personalized medicine. Increasing adoption of personalized medicine will drive sales of animal model in the forthcoming years.

Toxicity testing in animals is done to discover potential side effects from an agent's exposure and to generate dose-response relationships. Animal testing is important for the early detection of the potential risk to humans or as models to study the causes, pathogenesis, progression, and treatment of diseases.

Organizations and legislations such as the Federal Food, Drug, and Cosmetic Act (FFDCA), Environmental Protection Agency (EPA), Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), and Organization for Economic Co-operation and Development (OECD) determine the testing guidelines for toxicity testing on animals.

Some factors such as the high production volume of chemicals testing in the U.S., increasing generation and utilization of novel GM animal strains in toxicity studies, and the development and attempted validation of several animal tests to screen chemicals for endocrine (hormone)-disrupting activity are expected to drive the growth in the market.

Key Takeaways:

• Based on species, the mice model segment is expected to hold nearly 62.6% of the total market share 2022, with sales growing at a 5.1% CAGR.
• In terms of therapeutics, the oncology accounted for more than 32.0% of the total market share in 2021, and the trend is expected to continue over the forecast period.
• By application, sales in the drug discovery/development segment commanded 65.4% of the total market share in 2021.
• Based on end user, the academic & research institutes segment accounted 36.6% of the total market share in 2021.

For in-depth insights, Download a PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-14527

Key Players:

• Charles River Laboratories
• The Jackson Laboratory
• Taconic Biosciences, Inc.
• Genoway
• Envigo (Inotiv, Inc.)
• Marshall BioResources
• Janvier Labs
• Applied stem cells
• Biocytogen
• Transposagen Biopharmaceuticals, Inc. (Hera Bio Labs)
• Cyagen
• Ingenious targeting labs
• Crown Bioscience Inc. (JSR Corporation).
• Harbour Biomed
• Sinclair Bio Resources
• Alpha Genesis Inc.
• Creative Animodel
• DaVinci Biomedical Research Products, Inc

Market Competition

Key players operating in the U.S. animal model market are expanding their business through partnerships and acquisitions with other companies to improve their global footprint. Following are a few examples of acquisitions:

• In October 2021, The Jackson Laboratory completed the acquisition of Charles River Laboratories Japan's Research Models & Services (RMS), which allows advancement in the company's scientific improvements in basic research and drug discovery.
• In November 2021, Inotiv, Inc., which is a leading contract research organization (CRO) completed its acquisition of Envigo RMS Holding Corp. to expand its R&D sector.
• In February 2021, Biocytogen completed the acquisition of a third Beacon Optofluidic system. This acquisition expanded Biocytogen's service platform in the Boston area.

For in-depth competitive analysis, Buy Now @ https://www.futuremarketinsights.com/checkout/14527

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the animal model market in its latest study, presenting a historical demand assessment of 2017-2021 and projections for 2022- 2032.

The research study is based on the species - (rats, mice, pigs, rabbits, monkeys, dogs, cats, other species), therapeutics- (metabolic diseases, cardiovascular diseases, neurological diseases, and oncology), application (drug discovery/development and basic & applied research) end-user (academic & research institutes, pharmaceutical companies, biotechnology companies, and CROs) and across seven key regions of the world.

Future Market Insights' Expertise in Life Sciences and Transformational Health

Our expert team of industry analysts comprising management graduates, medical professionals, engineers, and project managers provides insights on emerging therapy areas, diagnostic tools, medical devices and components, reimbursement and market access, biotechnology, and life science research products and services to equip decision-makers with sound inputs and strategic recommendations.

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights,

Unit No: 1602-006,

Jumeirah Bay 2,

Plot No: JLT-PH2-X2A,

Jumeirah Lakes Towers,

Dubai,

United Arab Emirates

For Sales Enquiries: [email protected]

Browse All Reports : https://www.futuremarketinsights.com/reports

LinkedIn| Twitter| Blogs

The post U.S. Animal Model Market is anticipated to increase at a high CAGR of 4.1 % (2022-2032) appeared first on Future Market Insights.

Original Source of the original story >> U.S. Animal Model Market is anticipated to increase at a high CAGR of 4.1 % (2022-2032)

This content is published on behalf of the above source. Please contact them directly for any concern related to the above.

This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.